Diabetes & Obesity Drugs: Kidney Protection Benefits | Study Findings
- Glucagon-like peptide-1 (GLP-1) receptor agonists, initially developed for diabetes treatment, demonstrate significant kidney and cardiovascular advantages for a broad range of individuals, according to a comprehensive analysis published...
- These agonists, which include drugs like semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza), mimic the GLP-1 hormone, boosting insulin production and lowering blood sugar.
- While the benefits of GLP-1 receptor agonists are well-documented for type 2 diabetes, obesity, and cardiovascular disease, their impact on chronic kidney disease (CKD) had been less clear.
New research reveals meaningful kidney protection benefits with diabetes and obesity drugs, specifically GLP-1 receptor agonists.The study, analyzing data from over 85,000 participants, including those with type 2 diabetes, overweight, or cardiovascular disease, highlights a 16% reduction in kidney failure risk. These medications, like semaglutide (Ozempic, Wegovy), also showed cardiovascular advantages-potentially influencing future clinical guidelines. News Directory 3 provides in-depth coverage of this groundbreaking analysis. Investigate how these findings might reshape treatment strategies. Discover what’s next …
GLP-1 Agonists Show Kidney, Cardiovascular Benefits in New Analysis
Glucagon-like peptide-1 (GLP-1) receptor agonists, initially developed for diabetes treatment, demonstrate significant kidney and cardiovascular advantages for a broad range of individuals, according to a comprehensive analysis published in The Lancet Diabetes & Endocrinology.
These agonists, which include drugs like semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza), mimic the GLP-1 hormone, boosting insulin production and lowering blood sugar. They have also gained recognition as effective obesity treatments by slowing digestion and promoting satiety.
While the benefits of GLP-1 receptor agonists are well-documented for type 2 diabetes, obesity, and cardiovascular disease, their impact on chronic kidney disease (CKD) had been less clear. The meta-analysis encompassed 11 large clinical trials, involving 85,373 participants, including those with type 2 diabetes and overweight or obese individuals with cardiovascular disease but without diabetes.
The research revealed that GLP-1 receptor agonists reduced the risk of kidney failure by 16% and the worsening of kidney function by 22%, compared to a placebo. worsening kidney function was defined as a drop of at least 50% in estimated glomerular filtration rate. The combined risk reduction for kidney failure, declining kidney function, and kidney disease-related death was 19%. The analysis also validated the cardiovascular benefits, showing a 14% reduction in cardiovascular death, non-fatal heart attack, and non-fatal stroke.
overall mortality was 13% lower among patients treated with GLP-1 receptor agonists.
“this is the first study to show a clear benefit of GLP-1 receptor agonists on kidney failure or end-stage kidney disease, suggesting they have a key role in kidney-protective and heart-protective treatment for patients with common medical conditions like type 2 diabetes, overweight or obesity with cardiovascular disease, or CKD,” said Professor Sunil Badve, lead author and Professorial Fellow at The George Institute for Global Health and UNSW Sydney.
Badve emphasized the importance of these findings for CKD patients, noting the condition’s progressive nature, potential for kidney failure, and association with premature death and high healthcare costs.
CKD affects an estimated one in ten people globally, and is projected to become the fifth leading cause of death by 2050. Diabetes,cardiovascular disease,and obesity are major risk factors.
Professor Vlado Perkovic, also a Professorial Fellow at The George Institute and Provost at UNSW Sydney, highlighted the potential of GLP-1 receptor agonists in addressing the global burden of non-communicable diseases. He anticipates the study will significantly influence clinical guidelines for managing chronic kidney and cardiovascular diseases.
What’s next
Perkovic called for further work to translate these findings into clinical practice and improve access to GLP-1 receptor agonists for those who could benefit.